Right ventricular failure: A novel era of targeted therapy

被引：19

作者：

Banerjee D. ^{[1
]}

Haddad F. ^{[1
]}

Zamanian R.T. ^{[2
]}

Nagendran J.

机构：

[1] Division of Cardiovascular Medicine, School of Medicine, Stanford University, Stanford, CA 94305

[2] Division of Pulmonary and Critical Care Medicine, Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford School of Medicine, Stanford, CA 94305, 300 Pasteur Drive

来源：

Current Heart Failure Reports | 2010年 / 7卷 / 4期

关键词：

Biomarkers; Heart failure; Hypertrophy; Right ventricle; Therapy;

D O I：

10.1007/s11897-010-0031-7

中图分类号：

学科分类号：

摘要：

There now is strong evidence to recognize the pivotal role of the right ventricle (RV) in heart disease and to establish it as a unique and separate entity than the left ventricle (LV). Here, we summarize the differences between the two ventricles, the diagnosis of RV failure, and the management of acute and chronic RV failure. We review the indices derived by echocardiography used to measure RV function, and novel biomarkers that may play a role diagnosing and prognosticating in RV-specific disease. There are new novel therapies that specifically target the RV in disease. For example, phosphodiesterase type 5 inhibitors improve contractility of the hypertrophied RV while sparing the normal LV in pulmonary arterial hypertension. The metabolism of the hypertrophied RV is another area for therapeutic exploitation by metabolic modulation. We also suggest future potential molecular targets that may be unique to the RV because they are upregulated in RV hypertrophy greater than in LV hypertrophy. © 2010 Springer Science+Business Media, LLC.

引用

页码：202 / 211

页数：9

共 91 条

[61]

Lewis G.D., Shah R., Shahzad K., Camuso J.M., Pappagianopoulos P.P., Hung J., Tawakol A., Gerszten R.E., Systrom D.M., Bloch K.D., Semigran M.J., Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension, Circulation, 116, 14, pp. 1555-1562, (2007)

[62]

Jabbour A., Keogh A., Hayward C., MacDonald P., Chronic sildenafil lowers transpulmonary gradient and improves cardiac output allowing successful heart transplantation, European Journal of Heart Failure, 9, 6-7, pp. 674-677, (2007)

[63]

Klodell Jr. C.T., Morey T.E., Lobato E.B., Aranda Jr. J.M., Staples E.D., Schofield R.S., Hess P.J., Martin T.D., Beaver T.M., Effect of Sildenafil on Pulmonary Artery Pressure, Systemic Pressure, and Nitric Oxide Utilization in Patients with Left Ventricular Assist Devices, Annals of Thoracic Surgery, 83, 1, pp. 68-71, (2007)

[64]

Kulkarni A., Singh T.P., Sarnaik A., Walters H.L., Delius R., Sildenafil for pulmonary hypertension after heart transplantation, Journal of Heart and Lung Transplantation, 23, 12, pp. 1441-1444, (2004)

[65]

Schermuly R.T., Dony E., Ghofrani H.A., Pullamsetti S., Savai R., Roth M., Sydykov A., Lai Y.J., Weissmann N., Seeger W., Grimminger F., Reversal of experimental pulmonary hypertension by PDGF inhibition, Journal of Clinical Investigation, 115, 10, pp. 2811-2821, (2005)

[66]

Kerkela R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., Walters B., Shevtsov S., Pesant S., Clubb F.J., Rosenzweig A., Salomon R.N., Van Etten R.A., Alroy J., Durand J.-B., Force T., Cardiotoxicity of the cancer therapeutic agent imatinib mesylate, Nature Medicine, 12, 8, pp. 908-916, (2006)

[67]

Grimminger F., Weimann G., Frey R., Et al., First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension, Eur Respir J, 33, pp. 785-792, (2009)

[68]

MacChia A., Marchioli R., Marfisi R., Scarano M., Levantesi G., Tavazzi L., Tognoni G., A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology, American Heart Journal, 153, 6, pp. 1037-1047, (2007)

[69]

Lorenz C.H., Walker E.S., Morgan V.L., Et al., Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging, J Cardiovasc Magn Reson, 1, pp. 7-21, (1999)

[70]

Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., Picard M.H., Roman M.J., Seward J., Shanewise J.S., Solomon S.D., Spencer K.T., St John Sutton M., Stewart W.J., Recommendations for chamber quantification: A report from the American Society of Echocardiography's guidelines and standards committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology,

← 1 2 3 4 5 6 7 8 9 10 →